Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the esophagus, gastroesophageal junction, or gastric cardia for which no potentially curative or significant palliative therapy exists~  * Unresectable disease~ * Gastric cardia is defined as no more than 5 cm from the gastroesophageal junction into the stomach~* Measurable disease~* No known CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* At least 12 weeks~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than upper limit of normal (ULN)~* AST no greater than 3 times ULN~* Alkaline phosphatase no greater than 2 times ULN~Renal:~* Creatinine no greater than 1.5 times ULN~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No New York Heart Association class III or IV heart disease~Other:~* Able to swallow capecitabine~* No unresolved gastrointestinal bleeding~* No uncontrolled infection~* No chronic debilitating disease~* No peripheral neuropathy grade 2 or greater~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or adequately treated noninvasive carcinoma~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy or biological therapy for recurrent or metastatic disease~* No concurrent biologic agents~Chemotherapy:~* No prior chemotherapy for recurrent or metastatic disease~* Prior adjuvant or neoadjuvant chemotherapy (including combination chemotherapy and radiotherapy) allowed~* No other concurrent chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Chemotherapy~* No prior radiotherapy for recurrent or metastatic disease~* No prior radiotherapy to more than 25% of the bone marrow~* Prior adjuvant or neoadjuvant radiotherapy allowed~* More than 4 weeks since prior radiotherapy~* No concurrent radiotherapy~Surgery:~* More than 4 weeks since prior abdominal exploration with surgical resection~* More than 3 weeks since prior abdominal exploration without surgical resection~Other:~* No concurrent oral cryotherapy during oxaliplatin administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oxaliplatin + capecitabine (Type: EXPERIMENTAL): Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) receive 2 additional courses after CR.~Quality of life is assessed at baseline and then every 3 weeks (prior to each course of chemotherapy).~Patients are followed every 3 months for 1 year and then every 6 months for 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).